Posts

Showing posts from March, 2017

Pharma Innovation Yatra_March 2017

Pharma Innovation Yatra   was launched in the month of January 2017. This March the Yatra was at SIES Institute of Management in Navi Mumbai . The speaker interacted with the students doing their MBA in Pharmaceutical Management and Biotechnology management. The events were conducted with presentations on creative thinking, innovation and role of patents in the pharmaceutical industry. 1. Vivekanand Education Society’s College of Pharmacy. Website: https://ves.ac.in/pharmacy/ University: University of Mumbai. Location: Mumbai, Maharashtra. 2. M. C. E. Society’s Allana College of Pharmacy. Website: http://www.allanacollegeofpharmacy.org/ University: Savitribai Phule Pune University. Location: Pune, Maharashtra. 3. SVKM’s Dr. Bhanuben Nanavati College of Pharmacy. Website: http://www.bncp.ac.in/ University:

Patent filing feasibility study for M. Pharma students_Free of cost by Pharma Literati

As a commitment to the profession, we at pharma literati are offering free patentability analysis for the thesis of M. Pharma students. This is for the limited period till 30th April 2017. In this, a group of experts at pharma literati would assess the patentability of your M. Pharma thesis free of cost.  Eligibility: 1. M. Pharma students passing out in 2017; 2. The thesis has not been yet published as a research paper or presented in any conference; 3. Any students who passed out in 2016 are also eligible provided the institute allows them. 4. Anyone registered for Phd in pharmaceutical sciences in India and not yet submitted the thesis for the same.  Process: 1. With prior permission of the institute or University, the students need to make use of the service by pharma literati; 2.  The students would discuss the thesis or the novel aspect of the thesis with our experts; 3. If required, a confidentiality disclosure agreement is signed between the institut

Internship opportunities at Pharma Literati

Pharma Literati is pleased to announce the internship opportunities for undergraduate/ post-graduate students in pharmacy/ life sciences domain.  Looking for passionate, career-focused, highly motivated individuals who wish to join the dynamic team of Pharma Literati.  Profile:  The students would work on a collaborative project along with an industry expert for the purpose of original research work or review or literature survey or market research; Also, the students would work as bloggers for this tenure.  Location:  Work from home; Tenure:  2-3 months during summer vacation; Joining date: Flexible, after the examinations; Requirements:   Internet connection and laptop/desktop at home; Stipend:  No stipend in the form of cash; However, expenses if any, during the internship would be reimbursed; Also, few opportunities available to get benefited via different platforms;  Eligibility: B. Pharm/ M. Pharm students with basic understanding of internet

Lost interest in Fixed dose combinations

In spite of favourable court verdicts, top pharmaceutical companies are losing enthusiasm for fixed dose combination medicines. Early this year, the Indian arm of Pfizer decided to discontinue the manufacture and sale of Corex cough syrup, the crown jewel in its domestic portfolio. Corex was its biggest revenue generator and among the country’s top five drug brands. What made the decision more surprising was that Pfizer had fought a legal battle against a March 2016 Central government ban on sale of this fixed dose combination, or FDC, medicine, along with 333 others, and won. The decision to discontinue the syrup came a month after the court ruling. The government had banned these FDC drugs in March 2016 after a committee of experts found that they were likely to pose a risk to patients and safer alternatives were available. An FDC drug includes two or more active pharmaceutical ingredients combined in a single dosage form. Pfizer says the decision was based on a review of &

Hyderabad Univarsity inks MoU with Natco Pharma for research

University of Hyderabad (UoH) has signed an MoU with Natco Pharma for carrying out advance research in the areas of discovery of novel drugs and their delivery systems among others. According to a release issued by the university today, the research includes nano formulations of new chemical entities and novel biotechnological processes for specific products with potential commercial importance. Both the parties will promote cooperation in academic exchange, research and development collaborations, training and research in the areas of biotechnology, pharmacology, toxicology, pharmaceutical technology and organisation of national and international conferences, exhibition and similar events in areas of mutual interest, it said. School of Life Sciences of UoH has been undertaking collaborative research in the areas of drug discovery for the past several years with Natco. The research has resulted in developing one of the molecules to Phase-II clinical trials for the treatm

RGUHS mandates revision of theory question paper pattern for Pharmacy UG, PG & D Pharm courses from May

The Rajiv Gandhi University of Health Sciences, Karnataka has issued a draft notification for the revision of the theory question paper pattern in the Pharmacy of RS4 (regular and supplement) batch of undergraduate and post graduate courses. The notification will come into effect from May 2017. At its 124th syndicate meeting, the RGHUS has now taken a decision to revise the theory questions paper by offering no choices. Under section 35(1) of the RGHUS Act 1994, the Syndicate vide ref. No. 03 approved the recommendations of the BOS (Board of Studies) vide reference No. 1 and faculty of pharmacy vide reference No 2 to revise the theory question paper. For B Pharm, the revised question paper pattern will now mandate two long essays to be answered of 20 marks total. The candidate will also need to attempt all the 6 short essays of 5 marks taking the total to 30 marks. There will be 10 short answers of two marks each for a total of 20 marks. Pharm D students will have a simil

Pharma park on Jharkhand radar

If officials walk the talk, capital Ranchi could host Jharkhand's first ever pharma park, an idea promoted by the Union government on the lines of the present trend of earmarking geographical areas to develop specific industries like IT, pharma, auto etc. Jharkhand Infrastructure Industrial Development Corporation (JIIDCO), an arm of the state industries department, today floated expression of interest in search of agencies to prepare a detailed project and feasibility report, attract investments and handle other allied work to set up a pharma park. State industries director K. Ravikumar said the government had already earmarked around 50 acres at Itki and Sode areas near Ring Road on the outskirts of Ranchi. " During our field visits, we realised that both places could be suitable for pharma parks. Once a DPR is prepared and a feasibility report comes in, we would take a call on where to go ahead ," said Ravikumar, who is also MD of JIIDCO. The total co

Pharma in need of growth pill

The domestic pharmaceutical industry, which has often been in the spotlight for actions taken by the US drug regulator, could be staring at more disappointing news. The growth trajectory for the industry is expected to moderate following slowing growth from the US - its key market, increased competition, and a regulatory overhang, apart from the base effect. According to credit rating agency ICRA , revenue growth from the US between 2011 and 2015, which saw a compounded annual growth rate (CAGR) of 33 per cent, has come down to 15 per cent in 2015-16 and further down to 12 per cent in the nine-month period of this fiscal despite currency benefits. Further, there are limited major FTF (first to file) launches in the US market in the near term. As a result of all these factors, the base business is expected to continue to face competitive pressures, affecting growth from the US market. An FTF status for a generic drug gives the applicant a 180-day marketing exclusivity,

CDSCO to go online for all services in six months

The Central Drugs Standard Control Organisation (CDSCO) is set to become paperless within six months with completely shifting its services to online portal Sugam . The agency digitized 60-70 per cent of its services through Sugam portal so far. In another six months we are planning to go completely electronic for all our services by doing away with requirement of any physical documents, said a senior CDSCO official. With the launch of Sugam on November 14, 2015, firms can apply online for grant of registration certificates for import of drugs or import license of drugs in Form 10, under D&C Rules. They can also file online applications with respect to import registration and license of medical devices. Online submission has also been started for grant of approval to conduct bioequivalence studies for  export purposes. CDSCO has recently started process for online submission for clinical trial approval for Biologicals (Vaccines) on Sugam. Firms can request to test vacc